US Edition#Aligos Therapeutics to Present Eight Research Abstracts at EASL Congress 2025 Amidst Market Performance Challenges,
Summary by csimarket.com
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
All
Left
Center
Right
#Aligos Therapeutics to Present Eight Research Abstracts at EASL Congress 2025 Amidst Market Performance Challenges,
'Aligos Therapeutics Sets Stage for EASL Congress 2025 with Eight Accepted Abstracts' SOUTH SAN FRANCISCO, Calif. April 23, 2025 '' Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical-stage biopharmaceutical company dedicated to enhancing patient outcomes through advanced therapies targeting liver and viral diseases, today announced that eight of its research abstracts have been accepted for poster presentations at the European Association for …
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage
